STORM Therapeutics Secures €47.5 Million Series C to Revolutionize Cancer Treatment Through RNA Modification

In a significant boost to cancer treatment innovation, Cambridge-based biotech company STORM Therapeutics has successfully raised €47.5 million ($56 million) in a Series C funding round. This investment will propel the company’s pioneering work in RNA modification, aiming to reprogram cells for novel cancer therapies.

Pioneering RNA Modification

Founded in 2015, STORM Therapeutics is at the forefront of targeting RNA modifications to treat diseases by reprogramming malignant cells. The company's groundbreaking approach focuses on inhibiting RNA-modifying enzymes to influence cancer cell differentiation, offering a promising avenue for tackling various cancers.

Breakthrough in Cancer Treatment

STORM’s flagship candidate, STC-15, marks a groundbreaking development as the first RNA-modifying enzyme inhibitor to enter human clinical trials. Specifically targeting METTL3, an enzyme critical in cancer stem cell regulation, STC-15 shows potential in treating sarcomas—a cancer type originating in bone or soft tissues.

According to Jerry McMahon, CEO of STORM Therapeutics, advancing STC-15 into Phase 2 clinical development represents a pivotal moment. “This milestone highlights our scientific innovation and the potential to create new therapeutic options for patients with substantial unmet needs,” McMahon stated.

Funding and Future Prospects

The recent funding round was backed by existing investors, including M Ventures, Pfizer Ventures, and others. The capital raised will support the ongoing Phase 2 monotherapy study targeting sarcoma indications, with the first patient already dosed. The trial aims to establish a foundation for accelerated regulatory approval and further clinical development across additional oncology indications.

In Phase 1 trials, STC-15 demonstrated durable tumor regression across various sarcoma subtypes. These promising results underscore the potential of RNA modification to reprogram progenitor cells into cancer-fighting agents, with detailed findings to be presented at a medical conference in 2026.

Insights and Implications

For startups and investors, STORM Therapeutics’ progress signifies the burgeoning potential within the biotech sector, especially in RNA-based therapies. This innovation not only opens new treatment pathways for hard-to-treat cancers but also highlights the importance of supporting early-stage companies that focus on cutting-edge research and development.

The company's work emphasizes the role of RNA-modifying enzymes in maintaining stem cell-derived tumors, suggesting broader applications beyond sarcomas. As the biotech landscape evolves, the success of STORM Therapeutics could inspire further investment and innovation in RNA-based solutions.

Conclusion

STORM Therapeutics’ €47.5 million Series C funding is a testament to the growing confidence in RNA modification as a transformative approach to cancer treatment. With their lead candidate STC-15 advancing into Phase 2 trials, the company is poised to make significant strides in addressing critical unmet needs in oncology. This development not only represents hope for cancer patients but also highlights the potential for startups to drive groundbreaking innovations in healthcare.

Source: EU-Startups